DK2276346T3 - FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS - Google Patents

FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS Download PDF

Info

Publication number
DK2276346T3
DK2276346T3 DK09739460.5T DK09739460T DK2276346T3 DK 2276346 T3 DK2276346 T3 DK 2276346T3 DK 09739460 T DK09739460 T DK 09739460T DK 2276346 T3 DK2276346 T3 DK 2276346T3
Authority
DK
Denmark
Prior art keywords
compound
esi
aryl
heteroaryl
nmr
Prior art date
Application number
DK09739460.5T
Other languages
Danish (da)
English (en)
Inventor
Hsing-Pang Hsieh
Mohane Selvaraj Coumar
Tsu-An Hsu
Su-Ying Wu
Yu-Sheng Chao
Original Assignee
Nat Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Health Research Institutes filed Critical Nat Health Research Institutes
Application granted granted Critical
Publication of DK2276346T3 publication Critical patent/DK2276346T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK09739460.5T 2008-04-30 2009-04-22 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS DK2276346T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4906308P 2008-04-30 2008-04-30
PCT/US2009/041382 WO2009134658A2 (en) 2008-04-30 2009-04-22 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2276346T3 true DK2276346T3 (en) 2017-02-27

Family

ID=41255689

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09739460.5T DK2276346T3 (en) 2008-04-30 2009-04-22 FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS

Country Status (12)

Country Link
US (1) US8138194B2 (enExample)
EP (1) EP2276346B1 (enExample)
JP (1) JP5502072B2 (enExample)
KR (1) KR101667822B1 (enExample)
CN (1) CN102014627B (enExample)
AU (1) AU2009241469B2 (enExample)
CA (1) CA2722220C (enExample)
DK (1) DK2276346T3 (enExample)
ES (1) ES2616255T3 (enExample)
PL (1) PL2276346T3 (enExample)
TW (1) TWI363627B (enExample)
WO (1) WO2009134658A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515740A (ja) * 2009-12-23 2013-05-09 バイオクライスト ファーマシューティカルズ, インコーポレイテッド Janusキナーゼインヒビターとしての複素環式化合物
WO2011082273A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
TW201307347A (zh) 2010-11-01 2013-02-16 Arqule Inc 經取代苯並-咪唑並-吡啶並-二氮呯化合物
BR112014024251A8 (pt) * 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
JP6235001B2 (ja) 2012-05-21 2017-11-22 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ベンゾチエノピリミジン
CA2873971A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN103664993B (zh) * 2012-09-25 2016-05-25 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
EP2951187A1 (en) 2013-02-01 2015-12-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
MD20160112A2 (ro) 2014-04-25 2017-06-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105061461B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有苄胺结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CN105061460B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有硫醚结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106243124B (zh) * 2016-07-29 2018-03-09 湖北民族学院 一种噻吩并嘧啶脲类化合物及其制备方法和应用
BR112019003504A2 (pt) 2016-08-24 2019-05-21 Arqule, Inc. compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
CN106810512B (zh) * 2017-01-18 2019-09-10 江苏省中医药研究院 Idh2突变体抑制剂及其用途
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環mel-1抑制劑以及使用方法
CN111818917A (zh) * 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
US20200255451A1 (en) * 2017-08-15 2020-08-13 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
PL4021452T3 (pl) * 2019-08-26 2024-05-06 Chemwerth Inc Podstawione związki (7h-pirolo[2,3-d]pirymidyn-4-ylo)aminowe przydatne jako inhibitory jak1
CN112500421B (zh) * 2020-12-15 2021-08-24 河南科技大学第一附属医院 一种可用于杀菌消毒的苯并吡喃脲类化合物的制备方法及应用
TW202413367A (zh) * 2022-08-19 2024-04-01 財團法人國家衛生研究院 Tam受體抑制劑
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US6814324B2 (en) * 2002-07-03 2004-11-09 Segway Systems, Llc Releasably latchable leader block in tape threading apparatus for data storage systems and method therefor
BRPI0317717B8 (pt) 2002-12-24 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e uso de um composto
ATE437872T1 (de) * 2003-10-14 2009-08-15 Univ Arizona Proteinkinaseinhibitoren
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
HRP20080120T5 (hr) 2004-05-14 2012-07-31 Millennium@Pharmaceuticals Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
WO2006004658A2 (en) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
EP1781653A1 (en) 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
CN101160316A (zh) * 2004-07-16 2008-04-09 苏内西斯医药公司 适合用作aurora激酶抑制剂的噻吩并嘧啶
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
JP2009502801A (ja) 2005-07-22 2009-01-29 サネシス ファーマシューティカルズ, インコーポレイテッド Auroraキナーゼインヒビターとして有用なピラゾロピリミジン
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
RU2008120850A (ru) * 2005-10-28 2009-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназ
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제

Also Published As

Publication number Publication date
CN102014627B (zh) 2014-10-29
TWI363627B (en) 2012-05-11
WO2009134658A2 (en) 2009-11-05
EP2276346B1 (en) 2016-11-23
JP5502072B2 (ja) 2014-05-28
EP2276346A2 (en) 2011-01-26
CA2722220A1 (en) 2009-11-05
TW200948365A (en) 2009-12-01
AU2009241469B2 (en) 2015-05-07
HK1151694A1 (en) 2012-02-10
US8138194B2 (en) 2012-03-20
CN102014627A (zh) 2011-04-13
ES2616255T3 (es) 2017-06-12
EP2276346A4 (en) 2011-08-24
AU2009241469A1 (en) 2009-11-05
JP2011522789A (ja) 2011-08-04
WO2009134658A3 (en) 2009-12-30
KR20100132067A (ko) 2010-12-16
US20090275533A1 (en) 2009-11-05
CA2722220C (en) 2016-06-07
KR101667822B1 (ko) 2016-10-19
PL2276346T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
DK2276346T3 (en) FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORAKINASE INHIBITORS
EP2331530B1 (en) Fused multicyclic compounds as protein kinase inhibitors
JP5781934B2 (ja) チロシンキナーゼ阻害剤としての融合2環および3環ピリミジン化合物
KR102677015B1 (ko) Bet 억제제로서의 헤테로시클릭 화합물
WO2021239133A1 (zh) 作为axl抑制剂的嘧啶类化合物
EP2200437A1 (en) Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
CA2864672C (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN103373971B (zh) 作为蛋白激酶抑制剂的脲类化合物
HK1151694B (en) Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
KR20210026359A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
KR20210032357A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
MX2008009811A (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors